Skip to main content
Premium Trial:

Request an Annual Quote

Roche Diagnostics, Affibody, Quest Diagnostics, Thermo Electron

Premium

Roche Diagnostics has begun installing its West Nile virus blood-screening PCR systems at North American blood centers, in preparation for clinical trials scheduled to begin on or before July 1, the company said this week.

The test, which uses Roche’s PCR technology to amplify the genetic material of West Nile virus, is designed to help blood banks “ensure the safety” of blood and blood products used in transfusions and other procedures.

In the United States, Roche systems were installed at two America’s Blood Centers testing sites: the Gulf Coast Regional Blood Center, in Houston, and the Central Florida Blood Bank in Orlando; and also at the South Bend Medical Foundation testing site in Indiana.

In Canada, systems were installed at Canadian Blood Services and Hema-Quebec testing sites. Roche said it will continue installing the systems at other testing sites in the United States and Canada through May and June.


Affibody, of Stockholm, Sweden, and London-based InforSense have co-released the KDE GeneSense platform, which they say will allow researchers to interpret experimental genomics, transcriptomics, and proteomics data.

According to the companies, GeneSense combines InforSense’s Kensington Discovery Edition discovery-informatics environment with Affibody’s data management, ontology, and visual-representation technology.

GeneSense offers “curated access” to databases; links to KDE’s workflow system and analytical tools; interpretation using different ontologies; so-called “virtual chip” and “tree map visualizers” that display the ontologies; and an ontology-authoring tool that helps researchers build their own ontologies.

Quest Diagnostics and Thermo Electron plan to launch an automated, biochip-based prenatal diagnostic test for cystic fibrosis mutations, the companies said last week.

The new biochip array, called the CF Portrait, can be used for multiplex testing. It is currently used on a limited basis at Quest Diagnostics Nichols Institute in San Juan Capistrano, Calif., for cystic fibrosis-carrier screening. Researchers there are expected to use the CF Portrait for all such screenings by July 1.

The CF Portrait biochip is designed and manufactured by Thermo Electron's Thermo BioStar unit, part of the company's Clinical Diagnostics division, and uses its Optical ImmunoAssay technology.

Filed under

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.